3 Pharmaceutical Stocks Under $10 to Buy in September

NASDAQ: AMRX | Amneal Pharmaceuticals, Inc.  News, Ratings, and Charts

AMRX – The pharmaceutical industry’s increased focus on developing better treatments for many of today’s most complex diseases should help it to grow for the foreseeable future. However, because highly priced pharma stocks are susceptible to anticipated market volatility in the near term, we think it could be wise to bet on quality stocks Amneal Pharmaceuticals (AMRX), Catalyst Pharmaceuticals (CPRX), and Kamada (KMDA). These names are currently trading at affordable prices. Let’s discuss.

According to ReportLinker, the global pharmaceutical contract development and manufacturing market size is expected to grow at an 8.6% CAGR to $162.69 billion by 2026. However, because the stock market is expected to remain volatile in the near term on concerns over the impact of rising COVID-19 cases on the economic recovery, pharma stocks trading at high valuations could witness a pullback in the near term.

So, we think it could be wise to bet now on fundamentally sound stocks Amneal Pharmaceuticals, Inc. (AMRX), Catalyst Pharmaceuticals, Inc. (CPRX), and Kamada Ltd. (KMDA), which are currently trading below $10.

Click here to checkout our Healthcare Sector Report for 2021

Amneal Pharmaceuticals, Inc. (AMRX)

AMRX develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. The Hayward, Calif., company operates in three segments: Generics; Specialty; and AvKARE. The company sells its products through wholesalers, distributors, hospitals, and chain and individual pharmacies.

On June 7, 2021, AMRX launched Dihydroergotamine Autoinjector NDA for migraines and cluster headaches. Joseph Todisco, Chief Commercial Officer for Amneal Specialty, said, “The addition of the DHE autoinjector reflects our commitment to expand our Specialty portfolio by bringing impactful therapies that deliver differentiated value for patients in need.”

For the second quarter, ended June 30, 2021, AMRX’s revenue increased 15.2% year-over-year to $535.08 million. The company’s gross profit increased 47.3% year-over-year to $212.5 million. Its net income came in at $14.53 million compared to a $12 million loss in the year-ago period. Also, its EPS was  $0.10, versus an $0.08 loss in the previous year quarter.

AMRX’s revenue is expected to be $2.14 billion in the current year, representing a 7.2% year-over-year rise. In addition, the company’s EPS is expected to increase 39.7% year-over-year to $0.88 in the current year. Over the past year, the stock has gained 22.5% in price to close yesterday’s trading session at $4.95.

AMRX’s POWR Ratings reflect this promising outlook. The POWR Ratings assess stocks by 118 different factors, each with its own weighting. The stock has an A grade for Growth and Value, and a B grade for Sentiment.

Within the Medical – Pharmaceuticals industry, it is ranked #37 of 216 stocks. Click here to see the additional POWR Ratings for AMRX (Quality, Stability, and Momentum).

Catalyst Pharmaceuticals, Inc. (CPRX)

CPRX develops and commercializes therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. Its special products include Firdapse for LEMS and Ruzurgi for the treatment of pediatric LEMS patients. CPRX is headquartered in Coral Gables, Fla.

On June 28, 2021, CPRX announced an exclusive license and supply agreement with DyDo Pharma for the development and commercialization of Firdapse in Japan. The agreement is expected to enhance its logistics operation and the company’s revenue in the coming months.

CPRX’s revenue increased 22.8% year-over-year to $36.37 million for the second quarter, ended June 30, 2021. The company’s net income increased 24.6% year-over-year to $12.18 million, while its EPS came in at $0.11, up 22.2% year-over-year. Also, its operating income was  $15.84 million, up 54.0% year-over-year.

Analysts expect CPRX’s EPS to increase 41% year-over-year to $0.55 in its fiscal year 2022. Its revenue is expected to increase 20.3% year-over-year to $163.55 million in the next year. In addition, it has surpassed the consensus EPS estimates in three of the trailing four quarters. Over the past year, the stock has gained 48.8% in price to close yesterday’s trading session at $5.

CPRX’s strong fundamentals are reflected in its POWR Ratings. The stock has an overall B rating, which indicates a Buy in our proprietary rating system.

CPRX has an A grade for Value, and a B grade for Quality. Within the Medical – Pharmaceuticals industry, it is ranked #30. Click here to see the additional POWR Ratings for Sentiment, Growth, Stability, and Momentum for CPRX.

Kamada Ltd. (KMDA)

Headquartered in Rehovot, Israel, KMDA primarily develops, produces, and markets plasma-derived protein therapeutics for orphan indications. The company operates in two segments: Proprietary Products; and Distribution. It has strategic partnerships with Takeda Pharmaceutical Company Limited (TAK), PARI GmbH, and Kedrion Biopharma.

On June 2,  Kedrion and KMDA announced the FDA approval of KEDRAB label update, confirming safety and effectiveness in children. Amir London, CEO of KMDA, said, “We believe that this label update may support an increase of KEDRAB’s U.S. market share. We anticipate that sales of KEDRAB will continue to grow meaningfully in the U.S., capturing a significant portion of the estimated annual $150 million U.S. HRIG market.”

For the second quarter, ended June 30, 2021, KMDA’s total assets increased 5% year-over-year to $216.35 million. The company’s total current liabilities decreased 13.6% year-over-year to $26.15 million. Also, its cash flow from investing activities was  $10.63 million, compared to a $1 million loss in the year-ago period.

KMDA’s EPS is expected to increase 20.0% year-over-year to $0.12 in the next year. Over the past five years, the stock has gained 13.2% in price to close yesterday’s trading session at $5.36.

It’s no surprise that KMDA has an overall B rating, which equates to a Buy in our proprietary rating system. In addition, it has an A grade for Value, and a B grade for Stability.

KMDA is ranked #24 in the Medical – Pharmaceuticals industry. Click here to see the additional POWR Ratings for KMDA (Momentum, Quality, Growth, and Sentiment).

Click here to checkout our Healthcare Sector Report for 2021


AMRX shares were trading at $4.81 per share on Thursday afternoon, down $0.14 (-2.83%). Year-to-date, AMRX has gained 5.25%, versus a 20.00% rise in the benchmark S&P 500 index during the same period.


About the Author: Riddhima Chakraborty


Riddhima is a financial journalist with a passion for analyzing financial instruments. With a master's degree in economics, she helps investors make informed investment decisions through her insightful commentaries. More...


More Resources for the Stocks in this Article

TickerPOWR RatingIndustry RankRank in Industry
AMRXGet RatingGet RatingGet Rating
CPRXGet RatingGet RatingGet Rating
KMDAGet RatingGet RatingGet Rating

Most Popular Stories on StockNews.com


Updated 2024 Stock Market Outlook

The bull market continues to rage on with the S&P 500 (SPY) making new highs. That is the past...the question is what does the future hold? That is why 44 year investment veteran Steve Reitmeister provides this updated 2024 Stock Market Outlook to help you carve a path to outperformance the rest of the year. Read on below for the full story...

3 Energy Stocks Set to Soar Beyond Expectations

Given the geopolitical tensions, increasing global oil demand, and supply adjustments, the energy sector is poised for robust growth. Therefore, investors might consider investing in energy stocks TechnipFMC (FTI), Weatherford International (WFRD), and ChampionX (CHX), which are poised to exceed expectations. Keep reading…

Has Carnival (CCL) Stock Turned Into a Buy After Earnings Release?

Carnival Corporation (CCL) reported record revenue in its most recent quarter but still faces a negative bottom line. The collapse of Francis Scott Key Bridge brings more uncertainty to its financials. Given these events, what stance should one take with CCL stock? Read more to find out…

3 China Stocks Positioned for Long-Term Growth

Despite facing challenges, the Chinese economy has demonstrated resilience, as evidenced by recent robust industrial output and retail sales data. Given this outlook, it might be an opportune time to own three top-notch China stocks, JD.com, Inc. (JD), China Automotive Systems (CAAS), and Youdao, Inc. (DAO). Read on…

Investor Alert: “Buy the Rumor, Sell the News!”

Everyone knows that the Fed is going to cut rates at some point this year. That is the worst kept secret on the planet helping to explain how we keep making new highs for the for the S&P 500 (SPY). Unfortunately that creates an interesting predicament for stocks after rates are cut. Plus another hurdle in the 2024 Presidential election. Steve Reitmeister is here to share his insights on the market outlook along with a preview of his top 12 stocks to outperform. Read on for more...

Read More Stories

More Amneal Pharmaceuticals, Inc. (AMRX) News View All

Event/Date Symbol News Detail Start Price End Price Change POWR Rating
Loading, please wait...
View All AMRX News